Geron
在场
高管
查看带有其 23 名主要高管的组织结构图
Geron 搜索最多的简介
- John Scarlett, Chief Executive Officer and Chairman of the Board
- Robert Spiegel, Director
- Gaurav Aggarwal, Director
高管在Geron变化
- Jim Ziegler已作为Executive Vice President and Chief Commercial Officer加入公司 (新闻发布的2024九月10号).
- Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, 将于 20248月30 退休 (新闻发布的2024七月24号).
创建提醒
跟踪 Geron 的高管变动
生物技术
Geron 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Geron 的最新新闻稿
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
- Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
- View more press releases Close
通过电子邮件
